Apr 16 |
As more rare disease therapies launch, their prices are rising
|
Feb 28 |
Inhibrx reports Q4 results
|
Feb 28 |
Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
|
Feb 28 |
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
|
Jan 25 |
Pharma Stock Roundup: JNJ Reports Q4 Earnings, SNY Inks M&A Deal With INBX
|
Jan 24 |
Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More
|
Jan 24 |
Sanofi Expands Rare Disease Focus With Inhibrx's INBRX-101 Acquisition
|
Jan 24 |
Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?
|
Jan 23 |
Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi
|
Jan 23 |
Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of Inhibrx
|